Leonard Kaps1,2, Christian Labenz1,2, Peter R Galle1,2, Julia Weinmann-Menke1, Karel Kostev3, Jörn M Schattenberg1,2. 1. I. Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany. 2. Metabolic Liver Research Programme, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany. 3. Epidemiology, IQVIA, Frankfurt, Germany.
Abstract
BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease. Its role in the development of extrahepatic co-morbidities is under investigation. The impact of NAFLD on the development of chronic kidney disease (CKD) is incompletely understood. The aim of this study was to explore the potential contribution of NAFLD on CKD in Germany. METHODS: The Disease Analyzer Database covering 7.49 million cases in Germany was explored for patients diagnosed with NAFLD between 2000 and 2015 and was matched 1:1 to a cohort without NAFLD. Matching criteria included age, sex, physician, index year and co-diagnoses associated with CKD. The primary outcomes of this study were incidences of CKD and end-stage renal disease. RESULTS: A total of 48,057 patients with NAFLD were matched to 48,057 patients without NAFLD. Within 10 years of the index date, 17.1% of patients with NAFLD and 11.6% of patients without NAFLD were diagnosed with CKD (p < 0.001). On Cox regression analysis, NAFLD was significantly associated with the incidence of CKD (hazard ratio (HR) = 1.58, p < 0.001). This association remained significant across different age groups and subgroups such as patients with diabetes mellitus or arterial hypertension. There was no association between NAFLD and emerging dialysis therapy (HR = 1.25, p = 0.245). CONCLUSIONS: In this large database analysis in Germany, NAFLD constitutes an independent risk factor for CKD. Patients living with NAFLD should be monitored for a change in kidney function, facilitating therapeutic measures for kidney disease at an early stage.
BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease. Its role in the development of extrahepatic co-morbidities is under investigation. The impact of NAFLD on the development of chronic kidney disease (CKD) is incompletely understood. The aim of this study was to explore the potential contribution of NAFLD on CKD in Germany. METHODS: The Disease Analyzer Database covering 7.49 million cases in Germany was explored for patients diagnosed with NAFLD between 2000 and 2015 and was matched 1:1 to a cohort without NAFLD. Matching criteria included age, sex, physician, index year and co-diagnoses associated with CKD. The primary outcomes of this study were incidences of CKD and end-stage renal disease. RESULTS: A total of 48,057 patients with NAFLD were matched to 48,057 patients without NAFLD. Within 10 years of the index date, 17.1% of patients with NAFLD and 11.6% of patients without NAFLD were diagnosed with CKD (p < 0.001). On Cox regression analysis, NAFLD was significantly associated with the incidence of CKD (hazard ratio (HR) = 1.58, p < 0.001). This association remained significant across different age groups and subgroups such as patients with diabetes mellitus or arterial hypertension. There was no association between NAFLD and emerging dialysis therapy (HR = 1.25, p = 0.245). CONCLUSIONS: In this large database analysis in Germany, NAFLD constitutes an independent risk factor for CKD. Patients living with NAFLD should be monitored for a change in kidney function, facilitating therapeutic measures for kidney disease at an early stage.
Authors: Chris Estes; Quentin M Anstee; Maria Teresa Arias-Loste; Heike Bantel; Stefano Bellentani; Joan Caballeria; Massimo Colombo; Antonio Craxi; Javier Crespo; Christopher P Day; Yuichiro Eguchi; Andreas Geier; Loreta A Kondili; Daniela C Kroy; Jeffrey V Lazarus; Rohit Loomba; Michael P Manns; Giulio Marchesini; Atsushi Nakajima; Francesco Negro; Salvatore Petta; Vlad Ratziu; Manuel Romero-Gomez; Arun Sanyal; Jörn M Schattenberg; Frank Tacke; Junko Tanaka; Christian Trautwein; Lai Wei; Stefan Zeuzem; Homie Razavi Journal: J Hepatol Date: 2018-06-08 Impact factor: 25.083
Authors: Yvonne Huber; Marie Boyle; Kate Hallsworth; Dina Tiniakos; Beate K Straub; Christian Labenz; Christian Ruckes; Peter R Galle; Manuel Romero-Gómez; Quentin M Anstee; Jörn M Schattenberg Journal: Clin Gastroenterol Hepatol Date: 2018-12-20 Impact factor: 11.382
Authors: Mohammed Eslam; Philip N Newsome; Shiv K Sarin; Quentin M Anstee; Giovanni Targher; Manuel Romero-Gomez; Shira Zelber-Sagi; Vincent Wai-Sun Wong; Jean-François Dufour; Jörn M Schattenberg; Takumi Kawaguchi; Marco Arrese; Luca Valenti; Gamal Shiha; Claudio Tiribelli; Hannele Yki-Järvinen; Jian-Gao Fan; Henning Grønbæk; Yusuf Yilmaz; Helena Cortez-Pinto; Claudia P Oliveira; Pierre Bedossa; Leon A Adams; Ming-Hua Zheng; Yasser Fouad; Wah-Kheong Chan; Nahum Mendez-Sanchez; Sang Hoon Ahn; Laurent Castera; Elisabetta Bugianesi; Vlad Ratziu; Jacob George Journal: J Hepatol Date: 2020-04-08 Impact factor: 25.083
Authors: Aiko P J de Vries; Piero Ruggenenti; Xiong Z Ruan; Manuel Praga; Josep M Cruzado; Ingeborg M Bajema; Vivette D D'Agati; Hildo J Lamb; Drazenka Pongrac Barlovic; Radovan Hojs; Manuela Abbate; Rosa Rodriquez; Carl Erik Mogensen; Esteban Porrini Journal: Lancet Diabetes Endocrinol Date: 2014-05 Impact factor: 32.069
Authors: Kåre I Birkeland; Johan Bodegard; Jan W Eriksson; Anna Norhammar; Hermann Haller; Gerard C M Linssen; Amitava Banerjee; Marcus Thuresson; Suguru Okami; Elena Garal-Pantaler; Jetty Overbeek; Jil Billy Mamza; Ruiqi Zhang; Toshitaka Yajima; Issei Komuro; Takashi Kadowaki Journal: Diabetes Obes Metab Date: 2020-06-03 Impact factor: 6.577
Authors: Hannes Hagström; Leon A Adams; Alina M Allen; Christopher D Byrne; Yoosoo Chang; Henning Grønbaek; Mona Ismail; Peter Jepsen; Fasiha Kanwal; Jennifer Kramer; Jeffrey V Lazarus; Michelle T Long; Rohit Loomba; Philip N Newsome; Ian A Rowe; Seungho Ryu; Jörn M Schattenberg; Marina Serper; Nick Sheron; Tracey G Simon; Elliot B Tapper; Sarah Wild; Vincent Wai-Sun Wong; Yusuf Yilmaz; Shira Zelber-Sagi; Fredrik Åberg Journal: Hepatology Date: 2021-06-22 Impact factor: 17.298
Authors: Nooshin Ghodsian; Erik Abner; Connor A Emdin; Émilie Gobeil; Nele Taba; Mary E Haas; Nicolas Perrot; Hasanga D Manikpurage; Éloi Gagnon; Jérôme Bourgault; Alexis St-Amand; Christian Couture; Patricia L Mitchell; Yohan Bossé; Patrick Mathieu; Marie-Claude Vohl; André Tchernof; Sébastien Thériault; Amit V Khera; Tõnu Esko; Benoit J Arsenault Journal: Cell Rep Med Date: 2021-11-03
Authors: Christian Labenz; Karel Kostev; Angelo Armandi; Peter R Galle; Jörn M Schattenberg Journal: United European Gastroenterol J Date: 2021-07-20 Impact factor: 6.866